UK begins trials of new antibody treatment for COVID-19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ uk-begins-trials-new-antibody-treatment-covid19
As part of the government-backed Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trials, monoclonal antibodies

The UK on Monday began human trials of new antibody treatment for patients hospitalized with COVID-19.

As part of the government-backed Randomised Evaluation of COVID-19 (RECOVERY) Trials, monoclonal antibodies, or potent laboratory-made antibodies, will be given to about 2,000 patients in the coming weeks to see if they are effective against coronavirus.

The Phase 3 open-label trial in patients hospitalized with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.

"REGN-COV2 was specifically designed by Regeneron scientists to target the virus that causes COVID-19. RECOVERY will be the fourth late-stage randomized clinical trial evaluating REGN-COV2 and will add to our knowledge about how this novel antibody cocktail may help hospitalized patients in need," said George D Yancopoulos, President and Chief Scientific Officer of Regeneron, the biotech firm collaborating on the project.

"The world urgently needs new medicines to combat COVID-19, and well-designed trials to evaluate new treatment options will quickly help us learn which are most effective," he said.

Peter Horby, Professor of Emerging Infectious Diseases and Global Health at the University of Oxford's Nuffield Department of Medicine, is the chief investigator of the trial.

He said the study is aimed at determining whether REGN-COV2 is safe and effective in the context of a large-scale randomized clinical trial.

"We have already discovered that one treatment, dexamethasone, benefits COVID-19 patients, but the death rate remains too high so we must keep searching for others. The RECOVERY trial was specifically designed so that when promising investigational drugs such as REGN-COV2 became available they can be tested quickly," he said.

REGN-COV2 is the first specifically designed COVID-19 therapy being evaluated by RECOVERY.

Experts said that it was selected due to its emerging safety profile in humans, pre-clinical data showing it could protect against viral escape mutations, and prevention and treatment studies in non-human primates showing it reduced the amount of virus and associated damage in the lungs.

Professor Fiona Watt, Executive Chair of the UK's Medical Research Council, highlighted that the RECOVERY trial has previously found the "most clinically effective" treatment for COVID-19 so far in dexamethasone.

"The same UK-wide trial will now test a new treatment designed specifically to combat the virus that causes the disease. Monoclonal, or targeted, antibodies are already used to treat cancer and autoimmune diseases.

"The new trial will tell us whether antibodies that attack the virus can be an effective treatment for COVID-19," she said.

Martin Landray, Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford, said there are good reasons to be excited about the trials as it would provide a robust assessment of the effect the lab-manufactured monoclonal antibody combination treatment has on hospitalized patients.

"Up to now, we have largely been studying whether existing drugs can be re-purposed to tackle this new disease, but we now have the opportunity to rigorously assess the impact of a drug specifically designed to target this coronavirus," he said.

REGN-COV2 is currently being studied in two Phase 2/3 clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals.

The open-label RECOVERY trial will assess the impact of adding REGN-COV2 to the usual standard-of-care on all-cause mortality 28 days after randomization. Other endpoints include the impact on hospital stay and the need for ventilation.

Tags : #UK #Begins #COVID-19 #Trials #British

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026